Covaxin Production

The Serum Institute - which manufactured the Covishield COVID-19 vaccine developed by British pharma giant AstraZeneca - stressed on Wednesday that all its product packaging had "disclosed all rare to very rare side-effects", including TTS.

Bharat Biotech on Friday said it is temporarily slowing down production of its COVID-19 vaccine Covaxin across its manufacturing units.

COVID-19 Technology Access Pool (C-TAP) was launched in May last year for facilitating timely, equitable and affordable access of COVID-19 health products by boosting their supply.

The monthly vaccine production capacity of Covishield is planned to be increased from 11 crore doses to more than 12 crore doses per month and of Covaxin from 2.5 crore doses to around 5.8 crore, the Lok Sabha was informed on Friday.

Union Health Minister Mansukh Mandaviya on Friday held separate meetings with Serum Institute of India CEO Adar Poonawalla and Biological-E MD Mahima Dalta to discuss issues regarding COVID-19 vaccines.

Monthly production capacity of Covishield is projected to be increased to more than 120 million doses and of Covaxin to around 58 million doses by December, the government told Rajya Sabha today, citing information from the COVID-19 vaccine makers.

The supply of Bharat Biotech's Covaxin has been slowed down because the first few batches at the company's newest facility in Bengaluru were not of the right quality, a top government adviser has said.

With ramping up of production capacities, nearly 25 crore 'Made in India' vaccines are expected to be available by August, a senior official has said and noted that it will go a long way in meeting the target of vaccinating one crore people daily aga

Amid rising demand for COVID vaccines, Bharat Biotech on Friday said production and supply of Covaxin is a time-consuming process as various procedures and approvals need to be in place before it is made available for vaccination.

New shipments of Bharat Biotech's Covaxin have reached 30 cities in 30 days, the vaccine maker said this morning in a tweet as a shortage of doses continues to be a challenge in India's fight against coronavirus.

To address the shortage of COVID-19 jabs in the country, the government is exploring the possibility of boosting production of vaccines, including identifying manufacturing sites for indigenously developed Covaxin outside India, sources said.

Bharat Biotech on Thursday said it's planning to ramp up the manufacturing capacity of its COVID-19 vaccine, Covaxin, by an additional 200 million doses per year.

The central government and Bharat Biotech are willing to invite other companies which want to produce Covaxin to help scale up its production, a top government advisor said on Thursday, as India grapples with a dire shortage of vaccines.

After the centre announced Rs 4,500 crore to boost production of the Covishield and Covaxin vaccines, Serum Institute of India says it has borrowed from banks to begin ramp-up of its vaccine immediately instead of waiting for the government's aid to

To support vaccination campaigns in India and across the globe, Bharat Biotech has ramped up the manufacturing capacity of its COVID-19 vaccine, Covaxin, to 700 million doses per annum, the vaccine maker said on Tuesday.

The Serum Institute - which manufactured the Covishield COVID-19 vaccine developed by British pharma giant AstraZeneca - stressed on Wednesday that all its product packaging had "disclosed all rare to very rare side-effects", including TTS.

Bharat Biotech on Friday said it is temporarily slowing down production of its COVID-19 vaccine Covaxin across its manufacturing units.

COVID-19 Technology Access Pool (C-TAP) was launched in May last year for facilitating timely, equitable and affordable access of COVID-19 health products by boosting their supply.

The monthly vaccine production capacity of Covishield is planned to be increased from 11 crore doses to more than 12 crore doses per month and of Covaxin from 2.5 crore doses to around 5.8 crore, the Lok Sabha was informed on Friday.

Union Health Minister Mansukh Mandaviya on Friday held separate meetings with Serum Institute of India CEO Adar Poonawalla and Biological-E MD Mahima Dalta to discuss issues regarding COVID-19 vaccines.

Monthly production capacity of Covishield is projected to be increased to more than 120 million doses and of Covaxin to around 58 million doses by December, the government told Rajya Sabha today, citing information from the COVID-19 vaccine makers.

The supply of Bharat Biotech's Covaxin has been slowed down because the first few batches at the company's newest facility in Bengaluru were not of the right quality, a top government adviser has said.

With ramping up of production capacities, nearly 25 crore 'Made in India' vaccines are expected to be available by August, a senior official has said and noted that it will go a long way in meeting the target of vaccinating one crore people daily aga

Amid rising demand for COVID vaccines, Bharat Biotech on Friday said production and supply of Covaxin is a time-consuming process as various procedures and approvals need to be in place before it is made available for vaccination.

New shipments of Bharat Biotech's Covaxin have reached 30 cities in 30 days, the vaccine maker said this morning in a tweet as a shortage of doses continues to be a challenge in India's fight against coronavirus.

To address the shortage of COVID-19 jabs in the country, the government is exploring the possibility of boosting production of vaccines, including identifying manufacturing sites for indigenously developed Covaxin outside India, sources said.

Bharat Biotech on Thursday said it's planning to ramp up the manufacturing capacity of its COVID-19 vaccine, Covaxin, by an additional 200 million doses per year.

The central government and Bharat Biotech are willing to invite other companies which want to produce Covaxin to help scale up its production, a top government advisor said on Thursday, as India grapples with a dire shortage of vaccines.

After the centre announced Rs 4,500 crore to boost production of the Covishield and Covaxin vaccines, Serum Institute of India says it has borrowed from banks to begin ramp-up of its vaccine immediately instead of waiting for the government's aid to

To support vaccination campaigns in India and across the globe, Bharat Biotech has ramped up the manufacturing capacity of its COVID-19 vaccine, Covaxin, to 700 million doses per annum, the vaccine maker said on Tuesday.